Bellevue
Bellevue is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Bellevue.
Bellevue is a company.
Key people at Bellevue.
Bellevue Group AG is a Zurich-headquartered, publicly listed Swiss investment management firm specializing in active strategies for healthcare, small and mid-cap companies, and growth-oriented segments where expertise drives outperformance.[1][2][3] Its mission centers on delivering excellence in specialty investments through innovation, entrepreneurship, and client-focused active management, managing CHF 4.8 billion in assets (as of June 30, 2025) with over 90 employees across Switzerland, Germany, the UK, and USA, including more than 20 healthcare specialists with 30+ years of experience.[1][3] The firm's investment philosophy emphasizes high-conviction, bottom-up fundamental analysis, benchmark-independent portfolios, and strict risk management, avoiding top-down committees in favor of entrepreneurial team autonomy.[1][2] Key sectors include healthcare (its core competence, as one of Europe's largest investors), small/mid-caps, private equity in Swiss SMEs, and innovative themes like obesity solutions and AI in health.[1][3] Bellevue significantly impacts the startup and growth ecosystem by providing capital to under-served segments, launching targeted funds (e.g., Bellevue Obesity Solutions in 2023), and offering operating support through its network, fostering long-term value in complex markets.[3][5]
Founded in 1993 as an independent entity in Kusnacht (near Zurich), Bellevue Group AG evolved from a brokerage and corporate finance player into a focused asset manager.[1][3][5] Key partners and leaders include investment specialists like Achim Wagner (Fund Manager), Alexandra Egg (Investment Manager), and Andreas Kaltseis (Investment Director), operating from offices in Switzerland, Germany, and beyond.[5] A pivotal restructuring in 2017 discontinued non-core brokerage activities, sharpening its emphasis on healthcare and growth strategies.[3] Milestones include the 2018 acquisition of Mars Asset Management by subsidiary StarCapital (adding €320 million in assets), reaching CHF 1 billion in alternative investments for Swiss SMEs by 2021, and recent fund launches like Bellevue Entrepreneur Private (2021) and thematic funds in obesity and AI health (2023).[3] This trajectory reflects a consistent shift toward high-expertise, active management in fast-growing, inefficient markets.[1][2]
Bellevue rides megatrends in healthcare innovation, including AI-driven health (e.g., Bellevue AI Health fund), obesity treatments amid rising global rates, and biotech/small-cap growth, positioning it ahead of sector re-ratings expected in 2026 due to policy clarity, earnings visibility, and innovation pipelines.[3][7] Timing aligns with healthcare's discount valuations versus broader markets, fueled by capital inflows and new segments like GenAI applications.[1][7] Market forces favoring Bellevue include Europe's cyclical rebound for small/mid-caps (e.g., electrification drivers) and demand for active management in inefficient areas like private equity secondaries and VC.[5][7] The firm influences the ecosystem by channeling capital into startups and SMEs, launching accessible products like healthcare ETFs, and providing expertise that amplifies returns in under-served health tech and growth niches.[1][3]
Bellevue is primed for expansion through healthcare tailwinds, with 2026 forecasts highlighting strong sector momentum from innovation pipelines and re-ratings.[7] Upcoming trends like AI integration in health, obesity market growth, and small-cap rebounds will shape its trajectory, potentially scaling AUM beyond CHF 5bn via new funds and acquisitions.[1][3][7] Its influence may evolve toward greater global reach in alternatives and tech-health intersections, solidifying its role as Europe's healthcare investment leader—echoing its founding passion for specialty excellence in fast-evolving growth arenas.[1][2]
Key people at Bellevue.
